Kornimate/medical-research-clean huggingface dataset:
stereotactic body radiotherapy for spine tumors

Conditions: Spinal Metastases; Vertebral Metastases; Benign Spinal Tumors; Chordoma; Meningioma; Schwannoma; Neurofibroma; Paragangliomas; Arteriovenous Malformations

Summary: this study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (sbrt) for the treatment of spine metastases and benign spine tumors.

this study is a single site, non-randomized, prospective, phase iv trial. patients are composed of 2 groups:spine metastases or benign spine tumors. data collected will include patient demographics, pathology data, tumor stage, sbrt dose fractionation scheme, dose received by adjacent critical normal tissues, tumor recurrence data, and acute and late toxicities. follow up data will be collected during the patient's standard office visits. the anticipated duration of this study is 5 years

Eligibility criteria:
eligibility criteria: * patient age \>= 18 years * performance status of 0-3 * vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy * benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (avms). * established histologic diagnosis of a benign or malignant tumor of the spine. * arteriovenous malformation of the spine identified radiographically (no biopsy) * well-defined lesion involving no more than 2 adjacent vertebral levels or spinal segment * minimal spinal canal compromise that is not rapidly progressive. ideally, the tumor should not be within 5 mm of the spinal cord. * if chemotherapy is planned, ideally it should not have been given within 30 days of starting radiation and should not resume until at least 2 weeks after completing radiation. in addition, it is not recommended to perform sbrt when targeted anti-angiogenesis therapy is planned within 2 months of the procedure. * signed study-specific consent form exclusion criteria: * lesion involving \> 3 adjacent vertebral levels * overt spinal instability * neurologic deficit due to bony fragments/bony compression of neural structures * prior radiotherapy at the involved level(s) within 3 months of radiosurgery, more than one prior course of radiotherapy at the involved level(s), or more than 45 gy previous radiation exposure at the involved level(s) * rapidly progressive spinal cord compromise or neurological deficit * paralysis, or otherwise compromised motor function due to radiographically confirmed cord compression * patient unable to undergo an mri * pregnant or lactating women, due to potential exposure of the fetus to rt and unknown effects of rt on lactating females * patients with psychiatric or addictive disorder that would preclude obtaining informed consent

Keywords: stereotactic radiotherapy spinal metastases vertebral metastases benign spinal tumors
va video connect in hiv care

Conditions: HIV

Summary: the purpose of this research study is to see how effective the addition of video to home telehealth services is in helping patients with hiv to remain in care, which is vital to management of their illness. the investigators also want to understand how to best put the video to home services into practice.


Eligibility criteria:
inclusion criteria: * patient in the infectious diseases clinic at michael e. debakey va medical center (medvamc), houston, tx, with hiv infection * at least 18 years of age * able to speak english * able to consent to the use of vvc exclusion criteria: * unable to use or consent to use vvc, due to either significant physical or mental disability * incarcerated (though medvamc does not generally provide care for prisoners)

Keywords: hiv telemedicine
long-term results of bone cement in stapes surgery

Conditions: Otosclerosis

Summary: considering the long-term results of otosclerosis surgery performed in our clinic, it was observed that in addition to the improvement in air conduction hearing, which indicates conductive hearing, which is the main success of the surgery, there was also an improvement in bone conduction hearing, which indicates sensorineural hearing, in patients using bone cement. our study aimed to examine the effect of bone cement use in otosclerosis surgery on long-term hearing thresholds and bone conduction.

a retrospective review was conducted on records of patients who underwent stapes surgery between 2012 and 2020. comprehensive records were selected, and patients were summoned for clinic visits for thorough examinations. evaluation encompassed the average of air and bone conduction at 500, 1000, 2000, and 4000 hz.

Eligibility criteria:
inclusion criteria: * patients over the age of 18 who underwent stapedotomy with a diagnosis of otosclerosis exclusion criteria: * inadequate information in files

Keywords: stapedotomy otosclerosis
reducing pesticide exposure in minority families

Conditions: Disorders of Environmental Origin

Summary: this is a community-based participatory research program focusing on pesticide contamination in migrant farmworker families.

this is a continuation of a community-based participatory research program focusing on pesticide contamination in migrant farmworker communities. oregon health sciences university's center for research on occupational and environmental toxicology and the oregon child development coalition propose to extend the participatory research model that has been developed to increase community capacity and to build knowledge on the nature and extent of childhood exposures to pesticides and resulting health effects. the project includes involvement from representatives of academic institutions, child and family educational, health, and social services, and the agricultural community. we propose to extend our program of research beyond the state of oregon to accomplish the following specific aims: 1. develop and validate a pathway model of organophosphate pesticide exposure for children residing near tree fruit orchards, 2. conduct a longitudinal investigation of pesticide residue analysis, work practices, home characteristics and biological markers of exposure in migrant families residing in multiple homes and communities throughout a year, 3. evaluate specific neurobehavioral outcomes in latino children who speak spanish and indigenous languages, living in homes with measured pesticide residues and in children living in homes with minimal measurable pesticide residues, and 4. assess effectiveness of accepted methods of intervention including health education and environmental exposure reduction on changing behavior and reducing pesticide exposure in the migrant agricultural community. the project also includes mechanisms to strengthen and expand the partnerships among migrant farmworker communities to increase the capacity of the community to address issues of environmental exposures and health. training opportunities are provided for youth from the latino farmworker community in environmental issues in affected communities. in addition to measuring the outcome of our research interventions in modifying exposures to pesticides and resulting health effects we have incorporated a comprehensive evaluation plan including measures to document increased research capacity in the community, leveraging by obtaining additional funding for further efforts, sustainability, culturally appropriate tools, policy or systems change, and impact on the field.

Eligibility criteria:
working in agriculture.

Keywords: pesticide exposure organophosphate biomarkers of exposure poisoning occupational health
safety and benefits of using laryngeal mask airway to keep airway potency during fiber-optic bronchoscopy

Conditions: Respiratory Disease Undergoing Elective Bronchoscopy.; Chronic Obstructive Pulmonary Disease

Summary: bronchoscopy is a method of diagnosis and treatment of common respiratory diseases and lung recognized for many years. since the action takes place in the airways and in light of the use of sedation, when performing, the procedure requires caution to keep potent airway and breathing sufficient enough. most of the bronchoscopy done without the aid of equipment for advanced airway protection. during the operation done monitoring hemodynamics: such as blood pressure, pulse and respiratory such as percutaneous oxygen saturation and carbon dioxide. laryngeal mask airway (lma) - is a tool that has been shown to be effective in securing of airway respiratory activity during positive-pressure ventilation. several studies have shown that the use of lma is a convenient and safe while performing bronchoscopy for airways and lungs. however, most of the studies were for certain patient groups such as children, immuno-compromised patients. or benefits and safety lma in front of intubation during bronchoscopy. our aim to assess the safety and efficacy lma in not mechanically ventilated patients undergoing flexible elective bronchoscopy . another objective, to examine whether there is a special group of patients enjoy the lma more than others. patients will be divided randomly into two groups alternately by order, one patient study group and the next one to control. study group : lma is inserted under sedation and used during the procedure. control group - performing bronchoscopy under sedation without lma. about 50 people are needed each group.


Eligibility criteria:
inclusion criteria: * above 18 y.o * competency to sign informed consent. * room air oxygen saturation above 95% * stable hemodynamically and respiratory during the start procedure. * undergoing elective bronchoscopy. exclusion criteria: * pregnant women and special groups will not be included in the study.
proquad™ versus m-m-r ii™ and varivax™ in healthy children (v221-009)(completed)

Conditions: Measles; Mumps; Rubella; Varicella

Summary: this study will compare measles, mumps, rubella, and varicella vaccine (v221) and concomitant administration of varivax and m-m-r ii vaccines in healthy children.


Eligibility criteria:
inclusion criteria: * in good health * negative clinical history of varicella, shingles, measles, mumps, and rubella exclusion criteria: * previous receipt of measles, mumps, rubella and/or varicella vaccine either alone or in combination * any immune impairment or deficiency * exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination * vaccination with an inactive vaccine with in the past 14 days * vaccination with a live vaccine within the past 30 days * immune globulin or any blood product administered in the past 3 months
a study of incb059872 in relapsed or refractory ewing sarcoma

Conditions: Relapsed Ewing Sarcoma

Summary: the purpose of this study is to evaluate the safety and preliminary antitumor activity of incb059872 in participants with ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of ewing sarcoma and have progressed on or after standard therapies. * must not be a candidate for potentially curative therapy or standard-of-care approved therapy. * measurable disease by computed tomography or magnetic resonance imaging based on recist 1.1 as determined by site radiology. * eastern cooperative oncology group performance status 0 to 2. * willingness to avoid pregnancy or fathering children. exclusion criteria: * receipt of anticancer medications, anticancer therapies, or investigational drugs within protocol-defined intervals before the first administration of study drug. * must have recovered (≤ grade 2 or at pretreatment baseline) from adverse events (aes) from previously administered therapies except for stable chronic toxicities (≤ grade 2) not expected to resolve. * untreated brain or central nervous system (cns) metastases or brain/cns metastases that have progressed. * prior radiotherapy within 2 weeks of study treatment. a 1-week washout period is permitted for palliative radiation to non-cns disease with medical monitor approval. * laboratory values outside the protocol-defined range at screening. * history or evidence of bleeding disorder or active clinically significant bleeding requiring medical intervention.

Keywords: relapsed ewing sarcoma bromodomain-containing protein (brd) inhibitor lysine demethylase 1 (lsd1) inhibitor
an intergenerational community based participatory research (cbpr) intervention to reduce appalachian health disparities

Conditions: Overweight; Obesity

Summary: the study purpose is to evaluate the effectiveness of a culturally appropriate, faith-placed lay health advisor intervention aimed at increasing fruit and vegetable intake and physical activity among intergenerational appalachian individuals and families.

the developmental phase of this project incorporated community based participatory research (cbpr) principles to identify the needs and preferences of community members with regard to energy balance. in the intervention phase, this group-randomized trial administers and evaluates an intergenerational, culturally appropriate energy balance intervention aimed at increasing fruit and vegetable intake and increasing physical activity among participants in 6 distressed appalachian counties. faith institutions are recruited and randomized to treatment or wait-list control conditions, and participants are recruited and enrolled within those institutions. focusing on appalachian children, parents, and grandparents, local lay health advisors deliver a series of group presentations, adapted from we can! and media smart youth. in addition, the project provides culturally consonant leave-behind "booster" activities, including square dances, cooking classes, and community gardens.

Eligibility criteria:
inclusion criteria: * age 8 years or above * able to provide informed consent/assent

Keywords: overweight obesity appalachian intergenerational families energy balance group-randomized trial
navelbine and capecitabine in the treatment of metastatic breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to find the highest dose of capecitabine and oral navelbine that can be given without causing severe side effects, and to determine the safety, tolerability, and effects (good and bad) of capecitabine given with oral navelbine to patients with advanced breast cancer.

* not every patient will be receiving the same dose of capecitabine and navelbine. a small group will be enrolled onto the study and given certain doses of each drug. if they tolerate them well (have few or easily manageable side effects), the next small group of people enrolled will receive a higher dose of one of the drugs. this will continue until we find the highest doses of the drugs that can be given without causing serious or unmanageable side effects. * patients will be given oral navelbine on days 1 and 8 of each cycle, unless they are at the highest dose. in which case, they will be given navelbine on days 1, 8 and 15. capecitabine will be given on days 1-14 of each cycle in two divided doses approximately 12 hours apart. * while patients are on the study they will have the following tests and procedures performed: physical examination every 3 weeks; routine blood work every week; extensive laboratory tests every 3 weeks; disease status will be checked every 6 weeks (2 cycles) unless there are symptoms of disease progression. * the weekly treatment will continue unless there is disease progression or unacceptable side effects.

Eligibility criteria:
inclusion criteria: * histologically confirmed breast cancer with evidence of locally advanced or metastatic disease * female patients age 18 or older * no more than three prior chemotherapeutic regimens in the metastatic setting * anc \> 1,500/mm3 * platelet count \> 100,000/mm3 * sgot \< 3 x uln * bilirubin \< 1.5 x uln * performance status of 0 or 1 * at least 3 weeks since prior chemotherapy or 2 weeks since prior radiation, surgery or any anticancer investigational agent * able to swallow and retain oral medications * measurable disease exclusion criteria: * prior vinca alkaloids * active gastrointestinal disease or disorder * pregnant or lactating * serious co-morbid medical or psychological condition * prior bone marrow or stem cell transplant * prior documented severe sensitivity to 5-fu

Keywords: xeloda navelbine capecitabine metastatic breast cancer
outcomes of a deep inferior epigastric perforator flap program

Conditions: Breast Cancer

Summary: the purpose of this study is to analyze an institution's experience with starting a subspecialized diep flap program.

the purpose of this study is to analyze an institution's experience with starting a subspecialized diep flap program and to determine whether other hospitals would benefit from instituting a similar program. prior studies have compared the outcome from a diep flap program with that of tram flaps within the same center. other studies have calculated the cost of a diep flap and its complication rate. however, no one has examined the overall effects of a subspecialized reconstruction program and its impact on a health center. in this study, we will determine if the institutionalization of a diep flap program has increased our center's rate of breast reconstruction, as well as evaluate its outcomes and overall financial viability.

Eligibility criteria:
inclusion criteria: * intraductal carcinoma * lobular carcinoma * infiltrating ductal carcinoma * paget's disease * brca positive exclusion criteria: * inflammatory carcinoma of the breast

Keywords: breast reconstruction diep flap
lapatinib/carboplatin/paclitaxel in previously treated ovarian or breast cancer patients

Conditions: Ovarian Epithelial Cancer Stage III; Stage IV Ovarian Cancer; Stage IV Breast Cancer

Summary: the purpose of this study is to determine the effectiveness, safety, tolerability and best dose of lapatinib (gw572016) in combination with carboplatin and paclitaxel.

the mtd was found in the phase i portion of this study to be oral lapatinib 1000 mg per day for each 4 week cycle and paclitaxel 60 mg/m2 weekly x 3 of a 4 week cycle and carboplatin auc 2 weekly x 3 of a 4 week cycle.

Eligibility criteria:
inclusion criteria: * relapsed (stage iii or iv) ovarian, primary peritoneal, fallopian tube carcinoma patients. * stage iv metastatic breast cancer patients who have failed no more than four previous chemotherapies for stage iv disease. * ability to swallow and retain oral medications. * measurable disease exclusion criteria: * treatment with previous weekly carboplatin and paclitaxel. * no prior treatment with erbb targeting therapies such as erlotinib, gefitinib and cetuximab. * no concomitant requirement for medication classification as cyp3a4 inducers or inhibitors.
carotid atherosclerosis: metformin for insulin resistance study

Conditions: Coronary Artery Disease

Summary: hypothesis: treatment with metformin in overweight non-diabetic individuals with coronary heart disease and on standard cardiovascular risk reducing agents including statins will have a beneficial impact on carotid artery atherosclerosis compared to placebo. rationale: once subjects have a heart attack, they remain at much higher than average risk of another heart attack and stroke, despite the best current therapies to lower their cholesterol and blood pressure and thin their blood. many subjects with heart disease also have problems metabolising (i.e. processing) sugar even if they do not have diabetes. there is some evidence that metformin, a drug which improves sugar metabolism, decreases the risk of future heart attacks in diabetic patients. however, whether metformin further reduces the risk of heart disease beyond established treatments in people without diabetes is unknown. method: the investigators will test the ability metformin, a drug with proven safety, to slow the progression of furring up (known as atherosclerosis) of blood vessels in non-diabetic subjects with heart disease. this will be achieved by treating 2 groups of subjects with metformin and placebo pills respectively. to measure atherosclerosis, the investigators will carry out ultrasound scans of the big blood vessels in the neck at the start of the study, after 1 year and after 1.5 years of therapy.the investigators will then be able to assess whether metformin has had a beneficial impact.


Eligibility criteria:
inclusion criteria: * proven coronary heart disease (prior acute coronary syndrome, prior cabg or angiographically proven chd) * aged 35-75 years * elevated waist circumference as per the international diabetes foundation criteria (94 cm in men and 80 cm in women) * all patients will be on statin exclusion criteria: * pregnancy and/or lactation at screening * premenopausal woman not on contraception * known or newly diagnosed diabetes mellitus on oral glucose tolerance testing (ogtt will be performed on subjects with hba1c 6.0-6.9% and fasting plasma glucose \[fpg\] \< 7.0 mmol/l at screening18) * screening results: hba1c ≥ 7.0% and/or fasting plasma glucose ≥ 7.0 mmol/l * patients with acute coronary syndrome within the last 3 months * clinically unstable heart failure * uncontrolled angina * contraindications to metformin

Keywords: no diabetes mellitus elevated waist circumference
multi-center study of new medications to treat vaginal infections

Conditions: Vaginal Infection

Summary: the purpose of this study is to evaluate the safety and efficacy of terconazole/metronidazole gel in the treatment of vaginal infections


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of vaginal infection that is confirmed by laboratory testing and: * capable of providing written informed consent or assent * currently not menstruating and not anticipating menses during treatment * if heterosexually active, subject must be post-menopausal for ≥ 1 year, surgically sterile, or practicing an acceptable form of birth control * negative pregnancy test * other criteria as identified in the protocol exclusion criteria: * other infectious causes of vulvovaginitis * subject has recently used, or is expected to require the concomitant use of prohibited medications/products * nursing mother * use of any investigational drug within 30 days of enrollment * history of hypersensitivity to any ingredient/component of the formulations * other criteria as identified in the protocol
the effects of kinesiotaping on balance in children with down syndrome.

Conditions: Down Syndrome; Balance

Summary: this study aimed to explore the effects of kinesio tape applied to plantar soles on balance in children with down syndrome (ds). two groups including children with ds and a group with their typically developing peers evaluated. half of the children with ds took kinesio tape application to the plantar soles and the other half took sham taping application. all children evaluated with dynamic and static balance measurements and ds children evaluated immediately after taping and 45 minutes after taping again with the same measurements.

balance is one of the most problematic issues in children with ds. mechanoreceptors of plantar region of the foot helps to regulate human erect posture and balance. studies shows that inputs from foot sole give a positive effect in improving balance both in healthy and neurologically demaged subjects. kinesio tape is a supportive method in physiotherapy with it's proprioceptive input giving effects. it is aimed to show the acute effects of kinesio tape on balance parameters in children with ds.

Eligibility criteria:
the inclusion criteria for healthy children: * not having any orthopedic or neurological disorder * to understand and do the commands given * being willing to participate in the study the inclusion criteria for children with ds: * to have diagnosis of ds * not having any orthopedic or neurological disorder in addition the ds * to understand and do the commands given * being willing to participate in the study. exclusion criteria for all children: * auditory and visual problems (not using glasses) * operated in last 6 months prior to he study

Keywords: down syndrome postural balance kinesio taping